Abstract:
A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.
Abstract:
The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11 LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.
Abstract:
The present disclosure relates to complex comprising an engineered polypeptide having affinity for interleukin-6 (in the following referred to as IL-6) and an antibody or an antigen binding fragment thereof, wherein said engineered polypeptide having affinity for IL-6 belongs to a class of engineered polypeptides comprising the sequence EEX3X4AWX7EIHX11 LPNLX16X17X18QX20X21AFIX25X26LX28X29. The present disclosure also relates to the use of said complex as a therapeutic agent.
Abstract:
The present invention is within the field of administration of biopharmaceuticals. More specifically, the invention provides for oral administration of a compound comprising a moiety which confers a desired therapeutic activity; and a polypeptide moiety which binds to albumin.
Abstract:
The disclosure provides a method of separation of at least one ABD-containing molecule present in a liquid from other constituents in the liquid, comprising a step of affinity separation, in which step is used, as affinity ligand, an ABD binding polypeptide comprising an ABD binding motif BM, which motif consists of an amino acid sequence selected from EX2X3X4AX6X7EIX10X11LPNLX16X17X18QX20X21AFIX25X26LX28D (SEQ ID NO:166) and amino acid sequences with at least 89% identity thereto.
Abstract translation:本公开提供了一种将存在于液体中的至少一种含有ABD的分子与液体中的其它成分分离的方法,其包括亲和力分离步骤,其中使用步骤作为亲和配体,包含ABD的ABD结合多肽 结合基序BM,该基序由选自EX2X3X4AX6X7EIX10X11LPNLX16X17X18QX20X21AFIX25X26LX28D(SEQ ID NO:166)的氨基酸序列和与其具有至少89%同一性的氨基酸序列组成。
Abstract:
The present disclosure relates to polypeptides which bind to human epidermal growth factor receptor 3 (HER3) and to use of such polypeptides in imaging and therapy. The disclosure provides an HER3 binding polypeptide comprising a HER3 binding motif, which motif consists of the amino acid sequence EKYX4AYX7EIW X11LPNLTX17X18QX20 AAFIGX26 LX28D (SEQ ID NO:110)
Abstract translation:本公开涉及结合人表皮生长因子受体3(HER3)的多肽以及在成像和治疗中使用这些多肽。 本公开提供了包含HER3结合基序的HER3结合多肽,该基序由氨基酸序列EKYX4AYX7EIW X11LPNLTX17X18QX20 AAFIGX26 LX28D(SEQ ID NO:110)
Abstract:
HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.
Abstract:
Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
Abstract:
The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11 LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.
Abstract:
The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptides (in the following referred to as Aβ), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.